An error occurred while rendering this component.
Please consult your application support team.
Study description: TYGRIS (The TYSABRI Global Observational PRogram In Safety) was a 5-year, global, observational cohort study designed to capture long-term safety data in patients with MS treated with TYSABRI® (natalizumab). The incidence and pattern of treatment-emergent serious adverse events were examined in a postmarketing sample of 6434 patients who received TYSABRI, 2207 of whom enrolled in the US.
The TYGRIS study was funded by Biogen.